Epigenetic silencing of tumour suppressor genes is an important mechanism involved in cell transformation and tumour progression. The Set and RING-finger-associated domain-containing protein UHRF1 might be an important link between different epigenetic pathways. Here, we report that UHRF1 is frequently overexpressed in human prostate tumours and has an important role in prostate cancer pathogenesis and progression. Analysis of human prostate cancer samples by microarrays and immunohistochemistry showed increased expression of UHRF1 in about half of the cases. Moreover, UHRF1 expression was associated with reduced overall survival after prostatectomy in patients with organ-confined prostate tumours (Po0.0001). UHRF1 expression was negatively correlated with several tumour suppressor genes and positively with the histone methyltransferase (HMT) EZH2 both in prostate tumours and cell lines. UHRF1 knockdown reduced proliferation, clonogenic capability and anchorage-independent growth of prostate cancer cells. Depletion of UHRF1 resulted in reactivation of several tumour suppressor genes. Gene reactivation upon UHRF1 depletion was associated with changes in histone H3K9 methylation, acetylation and DNA methylation, and impaired binding of the H3K9 HMT Suv39H1 to the promoter of silenced genes. Co-immunoprecipitation experiments showed direct interaction between UHRF1 and Suv39H1. Our data support the notion that UHRF1, along with Suv39H1 and DNA methyltransferases, contributes to epigenetic gene silencing in prostate tumours. This could represent a parallel and convergent pathway to the H3K27 methylation catalyzed by EZH2 to synergistically promote inactivation of tumour suppressor genes. Deregulated expression of UHRF1 is involved in the prostate cancer pathogenesis and might represent a useful marker to distinguish indolent cancer from those at high risk of lethal progression.
INTRODUCTION
Prostate cancer is the most common cancer and the second most common cause of cancer death among men in the Western countries. There is a great need to find markers predictive of clinical progression and therapeutic strategies to prevent and manage advanced and metastatic disease. Inactivation of tumour suppressor genes in many types of cancers, including prostate cancer, is frequently due to epigenetic mechanisms. 1 Hypermethylation of CpG islands in gene promoters correlates with pathological grade, clinical stage and androgen-independence and histone-modifying enzymes such as histone deacetylases and histone methyltransferases (HMT) are frequently altered in prostate tumours. 2, 3 Overexpression of the Polycomb group proteins, such as EZH2, BMI1 and RING1, along with increased tri-methylation of histone H3K27 (H3K27me3) in prostate tumours are associated with metastatic diseases and poor clinical outcome. 4 --6 Overexpression of EZH2 has been linked to deregulated expression of erythroblast transformation-specific domain transcription factors and repression of tumour suppressor genes such as Nkx3.1 in prostate cancer. 7 Methylation of histone H3 lysine 9 (H3K9me2 --3) is involved in the physiological regulation of the transcriptional response to androgen stimulation in prostate epithelial cells and alterations of this process can promote tumour growth and progression. 8, 9 Altered patterns of DNA, H3K9 and H3K27 methylation are frequent in cancers and contribute to create aberrant chromatin domains associated with silencing of tissue-specific and tumour suppressor genes in prostate tumours. 10 Recent studies suggest the existence of 'bridge' proteins that connect protein and non-protein functions within the molecular complexes that control the histone code, DNA methylation and gene expression. The Set and RING-finger-associated (SRA) domain-containing protein UHRF1 (alias Np95 or ICBP90) is a good candidate for this 'bridge' function. UHRF1 seems to be a master regulator of the epigenetic modifications required to perpetuate the repressive state of target genes. 11 --19 In addition, there is evidence that UHRF1 can be an important player in carcinogenesis. UHRF1 binds to the promoters of tumour suppressor genes 16, 17, 20 and is overexpressed in human cancers. 20, 21 In this study, by integrating gene expression and protein analysis in large cohorts of clinical samples with functional experiments in cancer cell lines, we investigated whether UHRF1 could be a critical element in the interplay between DNA methylation and histone tail modifications determining inactivation of tissue-specific and tumour suppressor genes in prostate cancer.
RESULTS

UHRF1 is overexpressed in prostate cancer
We analysed a previously published gene expression data set from 68 organ-confined prostate cancer samples and 14 human normal prostate to examine the expression profile of UHRF1. 7 Genes that specifically marked the molecular transition from benign to malignant disease were identified by differential gene expression profile analysis.
7 UHRF1 was among the transcripts with highly statistically significant increase in tumours compared with normal prostate (P-value 2.9 Â 10
À5
; Figure 1a ). About 50% of tumour samples had levels of UHRF1 mRNA significantly higher than normal prostate, with very high expression in about 20% of the cases (Figure 1b) .
To confirm this finding, we evaluated the expression of UHRF1 by immunohistochemistry (IHC) in tissue microarrays that included a total of 226 samples of organ-confined prostate tumours and 14 samples of benign prostatic hyperplasia(Supplementary Table 1 ). UHRF1 staining was exclusively nuclear. UHRF1 expression was very low (p1% of positive cells) in benign prostatic hyperplasia. Among the 204 samples evaluable by IHC, the staining was positive in 87 samples (43%), being intense in about 15% of the samples (Figure 1c ). Staining was negative in the remaining tumours. Overall, the data from the IHC analysis of protein level were in good agreement with the gene expression data and confirmed the low or absent level of expression of UHRF1 in benign tissue and its activation in a quite large group of prostate tumours.
UHRF1 is required for growth and maintenance of the transformed phenotype in prostate cancer cells To understand the functional relevance of UHRF1, we evaluated its expression in immortalised and transformed prostate epithelial cells and various cancer cell lines. Immunoblotting showed that the expression of UHRF1 was low in immortalised normal prostate epithelial (LHS) cells and increased upon transformation with RAS in LHSR cells. Expression of UHRF1 was also higher in androgenindependent cells and more aggressive DU145 and PC3 cells compared with the androgen-dependent LNCaP cells (Figure 2a) . Thus, the expression of UHRF1 appears to be linked to both malignant transformation and progression in prostate epithelial cells.
To further establish the link between UHRF1 and malignant phenotype, we evaluated the consequence of UHRF1 knockdown (KD) in PC3 cells. Transient KD of UHRF1 (one transfection resulted in significant depletion of its expression---up to 90%, Figure 2b ). We observed decrease in cell proliferation (about fourfold at 120 h after treatment; P-value o0.0001) compared with control small interfering RNA (siRNA)-treated cells (Figure 2c ). Similar results were obtained with a distinct siRNA (Supplementary Figure 1) . Clonogenic survival in adherent conditions was also decreased about threefold (P-value o0.001) upon siRNA-mediated KD (Figure 2d ). Furthermore, anchorage-independent growth in soft agar was markedly reduced upon UHRF1 KD with up to ninefold reduction (P-value o0.001) in colony formation compared with control siRNA-treated cells (Figure 2e ). Altogether, these results showed that UHRF1 was necessary for growth and maintenance of the malignant phenotype of prostate cancer cells. Furthermore, these data indicate that a transient loss of UHRF1 (up to 7 days) is sufficient to activate a broad epigenetic switch resulting in significant long-term effect on the phenotype. Interestingly, similar effects were seen by knocking down other epigenetic effectors, such as EZH2, BMI1, Suv39H1 and G9a, that might interact and cooperate with UHRF1.
22
UHRF1 correlates positively with EZH2 in prostate cancer cells and prostate tumours As UHRF1 has a role in epigenetic mechanisms, we searched whether UHRF1 expression correlated with the level of other epigenetic effectors in the microarray data set from primary prostate tumours. 7 We found that tumours with elevated levels of UHRF1 had also high expression of EZH2 (correlation coefficient of 0.64; P-value o0.00001; Figure 3a and Supplementary Table 2), which is the main HMT responsible for H3K27me3. 23 UHRF1 and EZH2 shared about 33% of positively correlated genes ( Figure 3b and Supplementary Table 2 ). This correlation is of remarkable interest as overexpression of EZH2 is associated with poor clinical outcome and adverse pathological features in prostate cancer. UHRF1 there were also many genes known to be implicated in cancer development and specifically in prostate cancer (Figure 3a and Supplementary Table 2 ). The correlation between UHRF1 and EZH2 was confirmed in prostate cancer cell lines, where we also found that the H3K9 HMTs Suv39H1 and G9a followed a similar pattern of expression ( Figure 3e ). The expression of all these epigenetic effectors was higher in RAS-transformed LHSR cells and in the more aggressive prostate cancer cell lines (Figure 3e ). These results suggested that UHRF1 and key HMTs might be coordinately upregulated in prostate cancer cells. The positive correlation of UHRF1 expression with several cancer genes along with key epigenetic effectors such as EZH2 reinforces the hypothesis that UHRF1 might directly participate to gene networks implicated in tumour-promoting functions and deregulation of partially common set of genes.
UHRF1 correlates inversely with tumour suppressor and prostate-specific gene expression Consistent with its role in transcriptional repression, analysis of microarray data showed that UHRF1 was inversely correlated with many known tumour suppressor genes and prostate-specific genes ( Figure 3c and Supplementary Table 3) leading to the hypothesis that UHRF1 could contribute to the repression of tumour suppressor pathways and induction of a dedifferentiation programme in prostate epithelial cells. Interestingly, a subset of the downregulated genes showed similar correlation coefficients with EZH2 (Figure 3c ), suggesting that they might be commonly regulated by both factors. Remarkably, a parallel analysis showed that UHRF1 and EZH2 shared about 34% of negatively correlated genes ( Figure 3d ).
To support the findings made in clinical samples, we analysed the expression of the repressed genes in immortalized (LHS) and RAS-transformed (LHSR) prostate epithelial cells and prostate cancer cell lines. Semi-quantitative reverse transcriptase --PCR analysis showed lower expression of most of these genes (that is, APC, CDH1, RAS ACPP, SFRP1, RARb1, RARb2, PSP94 and Nkx3.1) in PC3 and RAS-transformed LHSR cells compared with LNCaP and LHS cells (Figure 3e ). Other genes found to be inversely correlated with UHRF1 in human tumour samples (that is, RUNX3, GAS2, CBX7, HOXD10, DACH2, EDNRB, SLC5A8 and PI3KCG) were feebly or not at all expressed in all the cell lines ( Figure 3e ). Few other genes were not differentially expressed between LNCaP and PC3 cells (Supplementary Figure 2) . Some of the low expressed genes, such as CDH1, 24 RARb2, PIK3CG, GAS2,
25
PSP94, 26 RASSF1a 27 and RUNX3, 28 have been previously shown to be negatively regulated by EZH2 in prostate tumours and cancer cell lines, thus, reinforcing the view that UHRF1 and EZH2 might co-regulate them. Altogether, these results show a correlation between overexpression of UHRF1 and downregulation of many tumour suppressor genes both in tumours and cell lines.
Depletion of UHRF1 reactivates tumour suppressor genes in prostate cancer cells To directly address the role of UHRF1 in silencing tumour suppressor and prostate-specific genes, we knocked-down UHRF1 Table 2 . (e) Reverse transcriptase --PCR analysis of UHRF1,EZH2, Suv39H1, G9a and genes frequently repressed in prostate tumours, in prostate epithelial cells (immortalized LH, Ras-trasformed LHSR cells) and in prostate cancer cell lines (low tumorigenic androgen dependent LNCaP, highly aggressive androgen independent (PC3). ., genes whose expression is negatively correlated with UHRF1 (microarray data) in human prostate tumours; %, genes identified as onco suppressors and/or involved in differentiation;
, tumour suppressor genes identified as repressed by EZH2 in prostate cancer; genes frequently methylated in prostate cancer and |, prostate-specific genes.
in PC3 cells for 6 days to achieve maximal (up to 90%, Figure 4b ) and prolonged silencing. In UHRF1-depleted cells, we observed consistent upregulation of CDH1 (Figures 4a --b , column si-UHRF1). Other genes, including Wnt antagonists APC and SFRP1, oncosuppressors RARb1, RARb2 and RUNX3, and prostate-specific genes, such as ACPP were also reactivated (Figure 4a , column si-UHRF1). Interestingly, genes that were silent or feebly expressed in prostate cell lines, such as GAS2, CBX7, HOXD10, DACH2 and EDNRB, were re-expressed as well (Figure 4a , column si-UHRF1). Furthermore, using nested PCR we were able to detect re-activation of genes whose expression was undetectable after 30 PCR cycles (Figure 4a , column si-UHRF1 nested PCR).
To test whether there was a convergence between genes repressed by UHRF1 and those targeted by HMTs we assessed the effects of EZH2, Suv39H1 and G9a KD in PC3 cells.
KD of EZH2 and Suv39H1 (Figure 4a , columns isEZH2 and si-SUV39H1, respectively) reactivated most of the genes re-expressed upon depletion of UHRF1, whereas none of them were affected by G9a KD (Figure 4a , column si-G9a). Thus, UHRF1, EZH2 and Suv39H1 KD gave substantially an overlapping pattern of gene reactivation, reinforcing the notion that the three proteins might converge on a common set of genes.
As UHRF1 assists DNMT1 and DNMT3a in the maintenance of DNA methylation, 11, 12, 14 we investigated whether depletion of UHRF1 affected the methylation status of promoter of genes repressed in PC3 cells. We took advantage of the human prostate cancer methyl-profiler DNA methylation PCR arrays (SABioscience, Frederick, MD, USA), which includes six of the genes re-expressed (APC, CDH1, SFRP1, SLC5A8, RARB and EDNRB) following UHRF1 KD.
The levels of promoter methylation in UHRF1-depleted cells for all the genes tested was strongly reduced independently from the initial levels of methylation, as indicated by either a reduced level at highly methylated sites or an increased level at hypomethylated sites (Figure 4c) . Thus, UHRF1 controls DNA methylation at the promoters of tumour suppressor genes in prostate cancer cells. Collectively, these data indicate that silencing of tumour suppressor genes in prostate cancer cells could be achieved via multiple, perhaps convergent, mechanisms involving on one side histone H3K9me3 and DNA methylation mediated by UHRF1, Suv39H1 and DNMTs and on the other side histone H3K27me3 catalyzed by EZH2. The concomitant activation of multiple epigenetic effectors may determine synergistic repression of tumour suppressor genes and promote tumour progression. UHRF1 binds to the promoter of silenced genes and controls binding of Suv39H1 and histone H3K9 methylation We performed chromatin immunoprecipitation on control, UHRF1-and Suv39H1-depleted PC3 nuclear cell extracts to assess UHRF1 occupancy on promoters of genes that were reactivated upon UHRF1 KD. Chromatin immunoprecipitation showed that UHRF1 was bound to adjacent regions in the promoters of CDH1, RARb2 and PSP94 and the binding was eliminated upon UHRF1 KD (Figures 5a--b, lane UHRF1) . Furthermore, UHRF1 KD caused a reduction of H3K9me3 and an increase of H3K9Ac, consistent with transcriptional reactivation (Figure 5b) . Analysis of other genes reactivated by UHRF1 KD showed the same pattern of histone modifications in their promoters (Supplementary Figure 3) . KD of Suv39H1 induced changes in the histone pattern similar to the UHRF1 KD, with decreased H3K9me3 and increased H3K9Ac. We found minor changes in the level of H3K27me3 in the promoter of all these genes in UHRF1-and Suv39H1-depleted cells (Figure 5b , lane H3K27me3). This is interesting since, in line with previous reports, 25, 26, 29 we show that these genes were also targeted by H3K27me3 and were reactivated by EZH2 KD (Figure 4a ). Finally, in Supplementary Figure 4 , we show that UHRF1 is required for the recruitment of DNMT3a to the promoter of CDH1 and that depletion of UHRF1 increases the levels of H3K4me3 on the same promoter. Figure 5B) , confirming the key role of UHRF1 in maintenance of the repressive chromatin state. The change in H3K9me3 upon UHRF1 KD suggested a direct functional link between UHRF1 and Suv39H1. Consistent with this hypothesis, we found that depletion of UHRF1 reduced the binding of Suv39H1 to the gene promoters (Figure 5b , lane Suv39H1). Conversely, KD of Suv39H1 did not alter the binding of UHRF1 (Figure 5b, lane UHRF1) . Thus, UHRF1 was required for binding of Suv39H1 and for H3K9me3 modification at these promoters, whereas Suv39H1 and H3K9me3 were not needed for recruitment of UHRF1. We then investigated whether UHRF1 and the HMT might be part of a common complex and eventually interact each other. Endogenous Suv39H1 co-immunoprecipitated with overexpressed myc-tagged UHRF1 (UHRF1-myc) in high-salt nuclear extracts of HEK-293 cells (Figure 6a , lane Suv39H1). Endogenous UHRF1, furthermore, was present in co-immunoprecipitates with an antibody against endogenous Suv39H1 in PC3 cells. Thus, UHRF1 might interact with Suv39H1 and, through this interaction, direct the recruitment of Suv39H1 to gene promoters. We did not detect any interaction of UHRF1 with G9a either in HEK-293 or in PC3 cells (Figures 6a and b) . Conversely, we found that EZH2 and Suz12 co-immunoprecipitated with myc-tagged UHRF1 in HEK-293 cells, and UHRF1 was immunoprecipitated with antibodies against EZH2 in PC3 cells (Figure 6a ).
UHRF1 positivity is associated with poor prognosis in prostate cancer patients Collectively, our data pointed to an important role of UHRF1 in promoting cell proliferation, maintenance of the transformed phenotype and epigenetic gene silencing in prostate cancer cell lines and prostate tumours. This led us to hypothesise that the molecular events driven by deregulated expression of UHRF1 would likely affect tumour progression and prostate cancer clinical behaviour. To test this hypothesis, we examined whether UHRF1 expression was associated with clinical outcome in the cohort of primary prostate cancer patients evaluated by IHC. We had long-term (410 years) clinical follow-up data and UHRF1 expression assessed by IHC in 204 patients. Kaplan --Meyer survival analysis revealed that patients with UHRF1-positive tumours had reduced overall survival after prostatectomy compared with patients with UHRF1-negative tumours (Figure 7) . The difference between the UHRF1-positive and -negative groups was highly statistically significant (Log rank test (Mantel --Cox) P-value o0.0001). The median survival was 10.4 and 12.4 years for patients with UHRF1-positive and UHRF1-negative tumours, respectively. Thus, UHRF1 positivity has a negative impact on patient survival after prostatectomy and appears to signal tumours more prone to progression. These data have important clinical implications as UHRF1 expression may identify a subgroup of prostate cancer patients with particularly aggressive disease and poor prognosis.
DISCUSSION
In this study, we provide evidence that UHRF1 serves as a crucial link between histone modifications, DNA methylation and epigenetic gene silencing and has an important impact on prostate cancer pathogenesis and progression. Moreover, UHRF1 appears as an important prognostic biomarker for prostate cancer.
UHRF1 RNA and protein levels were greatly increased in about half of the cases compared with normal prostate in microarray and tissue microarrays of human tumour samples. Moreover, positivity for UHRF1 by IHC was associated with reduced overall survival after prostatectomy in a large cohort of patients with organconfined prostate tumours. In prostate epithelial cell lines, we found that UHRF1 upregulation was linked to malignant transformation. UHRF1 KD in prostate cancer PC3 cells reduced proliferation and colony formation both in adherent and in nonadherent conditions, reflecting an important role in maintenance of the malignant phenotype. Consistent with a role in epigenetic gene silencing, increased expression of UHRF1 both in human prostate tumours and in cell lines correlated with reduced expression of several tumour suppressor genes that have a critical role in prostate cancer. 25,26,29 --37 Many of these genes were known to be negatively regulated by methylation of H3K27 on their promoters 24 --26 and to be reactivated by loss of EZH2. Both in prostate tumours and in cell lines, we found a striking correlation between UHRF1 and EZH2 expression, which suggests that the two proteins might have similar and complementary roles in epigenetic gene silencing and tumour progression, further supported by our in vivo and in vitro results. Indeed, experiments in PC3 cells demonstrated that both UHRF1 and EZH2 were critical for gene silencing, as KD of either gene resulted in reactivation of a common set of genes silenced in these cells. Interestingly, gene reactivation upon UHRF1 depletion was associated with demethylation and increased acetylation of H3K9, and DNA de-methylation on genes promoters, with no apparent effect on H3K27me3. Thus, UHRF1 may be part of an epigenetic network that, along with EZH2 leads to transcriptional reprogramming, de-differentiation and transformation by silencing tumour suppressor and prostatespecific genes (Figure 8) .
Unexpectedly, KD of G9a had no effect on any of the genes tested in PC3 cells. Instead, depletion of Suv39H1 induced their reactivation with concomitant loss of H3K9me3 from the promoters as seen with UHRF1 KD. Thus, these results uncover a specific link between UHRF1, SUV39H1 and H3K9 methylation with important implications for silencing of tumour suppressor genes. Although Suv39H1 has been mainly associated with repression of pericentromeric heterochromatin, 38 some reports indicate that this enzyme is involved in regulation of euchromatic genes, including CDH1, 39 and other oncosuppressors and oncogenes. 40 Most interestingly, we found that binding of Suv39H1 to gene promoters was reduced in cells depleted of UHRF1, suggesting that UHRF1 was directly involved in the recruitment of Suv39H1. Conversely, Suv39H1 was not needed for binding of UHRF1 to gene promoters. We also found that UHRF1 depletion induced promoter DNA demethylation, shedding new light on the mechanism that might coordinate histone modifications and DNA methylation to silence tumour suppressor and prostate-specific differentiation genes by providing additional evidence that they are interconnected.
Thus, our results suggest that epigenetic gene silencing is regulated in prostate cancer cells by two convergent mechanisms related to modifications at the level of H3K9 and H3K27 and associated with DNA methylation. Moreover, our results give support to the hypothesis that histone H3K9 and H3K27 methylation patterns are main drivers of epigenetic deregulation in prostate carcinogenesis 10, 41 by showing the coordinate activation of UHRF1 and EZH2 in prostate tumours and functional interaction between UHRF1 and Suv39H1.
The current model suggests that stable negative gene regulation would be achieved by DNA methylation following an initial facultative silencing by histone modifications. The interactions between DNA methylation and H3K9me2/3 to form a reinforcing silencing loop have robustly been demonstrated. 42 However, the relationship between DNA methylation and H3K27me3 is still controversial, as it has also been shown that EZH2-mediated H3K27me3 silencing of tumour suppressor genes in prostate and other tumours can be independent from DNA methylation. 25 Our data suggest that two parallel but not mutually exclusive epigenetic pathways based on H3K27me3 and H3K9me2/3 might simultaneously converge to repress tumour suppressor genes in prostate cancer cells (Figure 8) . Components of the two pathways, such as Suv39H1 or Suv39H2 and constituents of the PRC1 complex (Cbx7 and HPc2 and XPc2), have been found to coexist in common multiple protein complexes, 43, 44 which gives support to our results that show that UHRF1 co-immunoprecipitates with Suv39H1 and EZH2.
Altogether, our data indicate a prominent role of UHRF1 in the crosstalk between histone modifications and DNA methylation in prostate cancer and place UHRF1 at the core of the H3K9me2/3 and DNA methylation-dependent pathway. Interestingly, both UHRF1 and EZH2 recruit histone deacetylases to repress target genes 13, 17, 45 and this would support a model in which each of the two repressive complexes might per se be sufficient to keep downregulated a tumour suppressor gene (Figure 8 ). This could also explain why functional loss of either of the two proteins can Figure 8 . UHRF1 along with EZH2 coordinate epigenetic silencing of tumour suppressor genes in prostate tumours. UHRF1 (a) and EZH2 (b) independently repress tumour suppressors in prostate cancer by coordinating the tri-methylation of specific histone tail residues, H3K9 and H3K27, respectively, at the level of their promoters. UHRF1 also controls the methylation status of CpGs on DNA. Overexpression of both proteins (c) in prostate cancer determines the convergence of both mechanisms and a more strong repressive action on the promoters of tumour suppressor genes.
reactivate their targets: recruitment of histone acetyl transferase activity by loss of UHRF1 or Suv39H1 (H3K9Ac--- Figure 5 ) or EZH2 (H3K27Ac 25 ) could reactivate the gene. However, inactivation of only one of the two pathways might not be sufficient for longterm re-expression of the gene because the other pathway, not inactivated and still functional, might take over on the long run. This should be taken into account when planning the development of drugs that might selectively inhibit only one of the two pathways.
MATERIALS AND METHODS
Microarray data and correlation analysis RNA extracted from tissue samples was amplified and labelled using Ambion Message Amp I (Ambion, Grand Island, NY, USA) and hybridised on Agilent Human 1A glass arrays (Agilent, Santa Clara, CA, USA) using a dye-swap replication scheme as described. 7 Arrays were scanned with the Agilent B scanner and raw data files were loaded into the Resolver SE System (Rosetta Biosoftware, Cambridge, MA, USA) for data normalisation and processing applying the Agilent platform-specific error model. A commercial pool of RNA from organ donor healthy prostates (Becton Dickinson, Franklin Lakes, NJ, USA) was used as common reference. A log 2 gene expression matrix was created after combining dye-swap replicates. Expression data were filtered for s.d.40.5 across the samples, resulting in 5142 probes. Microarray data are MIAME compliant and have been deposited in the Gene Expression Omnibus (GEO accession no. GSE14206).
Immunohistochemistry
Tissue samples from patients with organ-confined prostate cancer treated with radical prostatectomy were collected at the Insespital (Bern, CH) with the approval of the Ethical Committee and patient's written informed consent. Histopathological and clinical data are shown in Supplementary  Table 1 . Tissue microarray containing samples from benign prostatic hyperplasia (n ¼ 14) and primary prostate tumours (n ¼ 226) were prepared from paraffin-embedded tissues as described previously. 46 IHC was carried out using anti-UHRF1 rat monoclonal antibody (1:20 dilution, LabVision Corporation, Kalamazoo, MI, USA) followed by incubation with secondary mouse anti-rat antibody (DAKO, Carpinteria, CA, USA). Two pathologists scored the tissue microarrays independently.
Survival analysis
Kaplan --Meier survival curves of patients grouped according to the tumour UHRF1 expression pattern were created using SPSS software (SPSS, Armonk, NY, USA). Patients (n ¼ 204) included in the analysis had been treated with radical prostatectomy, had clinical follow-up data and evaluable UHRF1 IHC staining.
Cell cultures and transfection methods
Human prostate carcinoma cell lines (LNCaP, DU-145 and PC3 cells) and HEK-293 cell line were obtained from the American Type Culture Collection (Manassas, VA, USA) and propagated in RPMI 1640 (EuroClone, Milan, Italy) as described previously. 47 LH and LHSR were developed by Hahn and co-workers 48 and were maintained in PrEC growth medium (PrEGM, Cambrex, Lonza Group, Basel, Switzerland). HEK-293 cells were transfected with pcDNA3.1(-)BMycHis vector or pcDNA3.1(-)BhUHRF1MycHis, using calcium --phosphate method. hUHRF1, hEZH2, hSuv39H1 or hG9a siRNA sequences (On-TARGETplus SMARTpool, Dharmacon RNA Technologies, Lafayette, CO, USA) and non-targeting Pool (Dharmacon) were transfected with INTERFERin siRNA transfection reagent (Polyplus transfection, Strasbourg, France) following the manufacturer's recommendations.
Cell growth, clonogenic and soft-agar assay Cell growth proliferation, clonogenic and soft-agar assays were performed as described previously. 49 Each experiment was carried out in triplicate and repeated at least three times.
Western blot analysis
Western blotting were carried out using whole-cell extracts obtained using Laemmli buffer or total proteins isolated using the NucleoSpin TriPrep kit (Macherey-Nagel GMH & Co KG, Dü ren, Germany), separated on 8 --10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to nitrocellulose membranes. Equal loading were checked out by glyceraldehyde-3-phosphate dehydrogenase.
Semiquantitative reverse transcriptase --PCR
The total RNA was isolated from cell lines with the NucleoSpin TriPrep kit, (Macherey-Nagel GMH & Co KG). cDNAs were synthesised using Superscript II (Invitrogen, Grand Island, NY, USA) and subsequent semiquantitative PCR reactions were carried out using GoTaq Hot-Start Polymerase (Promega, Madison, WI, USA) and primers in Supplementary Table 6 .
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed based on a modification of previously published methods. 50 Briefly, cells were treated with 1% formaldehyde and collected in 1Â phosphate-buffered saline. Cell pellets were re-suspended in lysis buffer and sonicated 10 s Â 18 times on ice (BRANSON S250 digital sonicator, Branson, Danbury, CT, USA). Sonicated chromatin was incubated overnight at 4 1C in dilution buffer with anti-immunoglobulin G, anti-UHRF1, anti-SUV39H1, anti-H3K9me3, anti-H3K27me3 or anti-H3K9Ac. One percent of the total lysate was used for input control. DNA was extracted by the phenol/chloroform/isoamyl alcohol, ethanol precipitated and resuspended in water. Chromatin immunoprecipitation products were amplified using GoTaq Hot-Start Polymerase (Promega) and specific primers (Supplementary Table 6 ).
Immunoprecipitation
Proteins were extracted from PC3 cells or HEK-293 transfected cells with the NucleoSpin TriPrep kit (Macherey-Nagel GMH & Co KG) and immunoprecipitation carried out as described previously. 
Chromatin conformation analysis
Cells were cultivated, transfected and silenced for UHRF1 as indicated above. EpiQ Analysis of chromatin state was performed using the EpiQ assay kit (Bio-Rad) following the manufacture's instructions.
